Company

Biotest - Innovation in haematology,
clinical immunology and intensive care medicine

Further information

Research and development

Specialist for Immune Sciences

Further information

Investor Relations

Create value for our shareholders

Further information

Patients

Biotest products save lives and offer new perspectives to chronically ill patients

Further information

Careers

Passionate to help us save lives?

Further information

Our product range

Haematology Clinical immunology Intensive care medicine

Haematology

For the treatment of Haemophilia A and B, Biotest AG manufactures two preparations which derive from human plasma and are designed for intravenous injection.

Further information

Clinical immunology

Biotest produces several antibody concentrates from human blood plasma which are available as ready-to-use solutions. Biotest offers the IVIG preparation Intratect and different hyperimmunoglobulins with increased antibody titers against cytomegaloviruses (CMV), hepatitis B viruses (HBV) or varicella zoster viruses (VZV).

Further information

Intensive care medicine

Biotest produces several human blood plasma derived concentrates for intensive care medicines. These include Pentaglobin, an IgM enriched immunoglobulin, and other intravenously administered solutions, for the treatment of severe bacterial infections, coagulation disorders, and volume- or protein-substitution.

Further information

Our development pipeline

	Phase 1	Phase 2	Phase 3	Approval	Launch
	IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
	IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
	Fibrinogen (BT524) - Congenital fibrinogen deficiency
	Fibrinogen (BT524) - Acquired fibrinogen deficiency
	Trimodulin (BT588) - Severe community acquired pneumonia
	Indatuximab Ravtansine (BT-062) - Multiple myeloma
	Indatuximab Ravtansine* (BT-062) - Solid tumors

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

* Further information under News from research

Press releases

Biotest receives Intratect(R) approval for additional i...

24.01.2019,

Biotest receives Intratect(R) approval for additional indications in 22 European countries- Additional fields of use in neurology (CIDP, MMN) and secondary immunodeficiencies (SID) - 40% of the global ... [More]

Correction of a release from 11/12/2018 according to Ar...

12.12.2018,

Notification of Major Holdings1. Details of issuer Name: Biotest AG Street: Landsteinerstraße 5 Postal code: 63303 City: DreieichGermany Legal Entity Identifier (LEI): 529900JVX7RPXBLYUD892. Reason fo ... [More]

Release according to Article 40, Section 1 of the WpHG ...

11.12.2018,

Notification of Major Holdings1. Details of issuer Name: Biotest AG Street: Landsteinerstraße 5 Postal code: 63303 City: DreieichGermany Legal Entity Identifier (LEI): 529900JVX7RPXBLYUD892. Reason fo ... [More]

Biotest AG takes next step in developing a new haemophi...

04.12.2018,

Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs - Biotest exercises its option and receives exclusive rights for haemophilia on the use of Affibody's Alb ... [More]

Hepatect(R) CP and Zutectra(R) show marked efficacy in ...

20.11.2018,

Hepatect(R) CP and Zutectra(R) show marked efficacy in the prevention of HBV reinfection after liver transplantation in long-term study- 371 liver transplanted patients observed over almost seven year ... [More]

Biotest AG acquires ninth plasma collection center in G...

15.11.2018,

Biotest AG acquires ninth plasma collection center in Germany- 100% subsidiary Plasma Service Europe takes over plasma centre in Hanover- In the future, 20 plasma collection centres in Europe to ensur ... [More]

Biotest increases sales in the first nine months of 201...

14.11.2018,

Biotest increases sales in the first nine months of 2018 to EUR 289.6 million- EBIT of EUR 5.1 million despite expenses of EUR 37.8 million for the Biotest Next Level project- Successful qualification ... [More]

Preliminary announcement of the publication of quarterl...

12.11.2018,

Biotest AG hereby announces that the following financial reports shall be disclosed for the business year 2019: Report: Quarterly financial report within the 1st half-year (Q1) Date of disclosure / ... [More]

Preliminary announcement of the publication of financia...

12.11.2018,

Biotest AG hereby announces that the following financial reports shall be disclosed for the business year 2018: Report: Annual financial report Date of disclosure / German: March 28, 2019 Date of d ... [More]

Biotest AG announces successful completion of Mutual Re...

21.08.2018,

Biotest AG announces successful completion of Mutual Recognition Procedure for marketing authorization of Cytotect(R) CP Biotest in twelve European countries- Approval in four additional attractive Eu ... [More]

Cytotect(R) CP prevents transmission of Cytomegalovirus...

15.08.2018,

Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time- Transmission of CMV from pregnant women to the foetus i ... [More]

Biotest increases revenues to EUR 200.7 million in the ...

14.08.2018,

Biotest increases revenues to EUR 200.7 million in the first half of 2018- EBIT of EUR 0.6 million despite expenses of EUR 23.7 million for the Biotest Next Level project- Successful qualification of ... [More]

Biotest has closed a transaction to sell all of its pla...

01.08.2018,

Biotest has closed a transaction to sell all of its plasma collection centres in the United States to Grifols- Federal Trade Commission (FTC) approved sale of Biotest US Corporation and its operating ... [More]

Phase IIa study demonstrates favorable safety and toler...

19.07.2018,

Phase IIa study demonstrates favorable safety and tolerability profile for Biotest's monoclonal antibody BT-063 for treatment of systemic lupus erythematosus (SLE)- Study meets primary endpoint for sa ... [More]

Biotest AG opens third plasma collection centre in Czec...

20.06.2018,

Biotest AG opens third plasma collection centre in Czech Republic- 19 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 20 June 2018. Biotest received an operating permit ... [More]

Release according to Article 40, Section 1 of the WpHG ...

20.06.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights Acquisit ... [More]

Large data analysis for DSA after lung transplantation ...

29.05.2018,

Large data analysis for DSA after lung transplantation confirms impressive therapy outcome with Pentaglobin(R)- The development of donor specific antibodies (DSA) can lead to graft rejection and thus ... [More]

Efficacy and safety of Cytotect(R) CP was demonstrated ...

23.05.2018,

Efficacy and safety of Cytotect(R) CP was demonstrated in patients after stem cell transplantation- 78% of "difficult-to-treat" patients responded to Cytotect(R) CP administration- 70% of patients cle ... [More]

Biotest increases revenues in the first quarter 2018 by...

15.05.2018,

Biotest increases revenues in the first quarter 2018 by 34%- Guidance confirmed- Q1 EBIT totalled to EUR -3.0 million after EUR-33.2 million in Q1 2017Dreieich, 15 May 2018. In the first quarter of 20 ... [More]

Biotest AG: Annual general meeting approves payout of d...

15.05.2018,

Biotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.04 per preference shareDreieich/ Frankfurt a. M., 15 May 2018. At the annual general meeting (AGM) held on 15 M ... [More]

Careers

Careers

Passionate to help us save lives?

Further information

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Further information